The Rainbow Study - the Effect of Feedback on Asthmatic Symptom Perception
Launched by MEDISCH SPECTRUM TWENTE · Nov 22, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
The Rainbow Study is a clinical trial aimed at understanding how children with asthma feel and report their symptoms. Asthma can make it hard for kids to play and exercise, and sometimes they don't accurately recognize how bad their symptoms are. This study uses a special tool called the Rainbow Tool to help visualize their symptoms and lung function. Researchers want to see if regularly measuring lung function and giving personal feedback can help improve the way these children perceive their asthma symptoms.
To be eligible for the study, children must be between 7 and 15 years old and have a diagnosis of asthma from a pediatrician. They should also be able to understand Dutch and have a healthcare professional who thinks they might not be feeling their symptoms correctly. Participants will undergo lung function tests and report their symptoms throughout the study. This trial is currently looking for participants, and if your child qualifies, they may benefit from learning more about their asthma while helping researchers find better ways to manage the condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Selection phase:
- • Pediatrician diagnosed asthma
- • Health care professional thinks perception might be poor
- • Age 7 until 15 years old
- • Adequate understanding of Dutch language
- Intervention phase:
- * Adequate number of lung function measurements + VAS scores during selection phase, defined as:
- • At least 4 measurements after exercise or when experiencing symptoms and
- • At least 2 standard measurements
- * Poor perception during selection phase, defined as:
- • At least 1 measurement in red zone on Perception Rainbow and/or
- • At least 2 measurements in orange zone on Perception Rainbow and/or
- • Average of all measurements after exercise or when experiencing symptoms in yellow zone (or orange/red)and/or
- • Average of all measurements in yellow zone (or orange/red)
- Exclusion Criteria:
- • Severe comorbidity (for example psychomotor retardation or severe cardiopulmonary conditions)
- • Not able to fill in VAS score (for example due to blindness)
- • Not able to perform technically correct spirometry manoeuvres
- • Medication change in past 2 weeks
- • Exacerbation which required oral prednisone in the past 6 weeks
- • Exacerbation at the moment of inclusion
- • No device (computer, tablet or smartphone) with internet connection available at home
About Medisch Spectrum Twente
Medisch Spectrum Twente (MST) is a leading healthcare institution located in the Netherlands, dedicated to providing high-quality medical care and advancing clinical research. As a regional hospital, MST is committed to improving patient outcomes through innovative treatment options and comprehensive clinical trials. The institution fosters collaboration among multidisciplinary teams of healthcare professionals, researchers, and academic partners, ensuring a robust environment for conducting research that adheres to the highest ethical standards. MST's focus on patient-centered care and its strategic initiatives in clinical research contribute significantly to the advancement of medical knowledge and the development of effective therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Enschede, Ov, Netherlands
Patients applied
Trial Officials
Vera Hengeveld, MD
Principal Investigator
Medisch Spectrum Twente
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported